Clinical trials: Venous Thromboembolic Event
Trauma, Surgery
Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)
The risk of developing a blood clot occurs in up to 60% of all critical care patients. Many times enoxaparin (or Lovenox) is given to patients who are at a higher risk of developing clots in their legs or lungs.
- Conditions
- Trauma, Surgery, Deep Vein Thrombosis (DVT), Thromboembolic Events
- Trial name
- NCT02342444
- Testing
- Enoxaparin Sodium Injection 30 mg BID, Enoxaparin Sodium Injection 40 mg QD
- Where
- United States
- Volunteers
- 606 people
- Sponsor
- Oregon Health and Science University
Venous Thrombosis, Pulmonary Embolism
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)
This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Acenocoumarol for the first…
- Conditions
- Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Acute Coronary Syndrome
- Trial name
- NCT01947985
- Testing
- Rivaroxoban (Xarelto, Bay59-7939), Standard of care
- Where
- Netherlands
- Volunteers
- 208,958 people
- Sponsor
- Bayer
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia
Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia
This pilot clinical trial compares the safety of two different platelet transfusion "thresholds" among patients with blood cancer or treatment-induced thrombocytopenia whose condition requires anticoagulant medication (blood…
- Conditions
- Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, B-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT03195010
- Testing
- Platelet Transfusion
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Fred Hutchinson Cancer Center
Venous Thromboembolism, Brain Tumors
Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients
In patients with malignant glioma, to determine the efficacy of prophylaxis with LMWH (dalteparin) compared to placebo, both commenced beyond the immediate postoperative period, for the prevention of VTE.
- Trial name
- NCT00135876
- Testing
- dalteparin
- Where
- 14 sites in United States, Australia and 2 more
- Volunteers
- 512 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Venous Thromboembolism, Deep Vein Thrombosis
Detecting the Impact of Statin Therapy On Lowering Risk of Venous Thrombo-Embolic Events (DISOLVE)
Patients with cancer have a high risk of developing venous blood clots or thromboembolism (VTE). In an effort to target patients at highest risk of VTE for thromboprophylaxis (protective treatment for blood clots), numerous…
- Conditions
- Venous Thromboembolism, Deep Vein Thrombosis, Neoplasms
- Trial name
- DISOLVE (NCT01524653)
- Testing
- Rosuvastatin
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Vermont
Arthroplasty, Replacement, Prevention of Venous Thromboembolism
Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate
To supplement the current evidence of the effect of Pradaxa® (dabigatran etexilate) on coagulation parameters, including a calibrated thrombin time test, in patients with moderate renal impairment undergoing elective total hip…
- Conditions
- Arthroplasty, Replacement, Prevention of Venous Thromboembolism, Moderate Renal Impairment (CrCl 30-50 mL/Min)
- Trial name
- NCT01184989
- Testing
- Dabigatran etexilate
- Where
- 10 sites in Austria, Canada and 4 more
- Volunteers
- 142 people
- Sponsor
- Boehringer Ingelheim
Obstructive Sleep Apnea, Venous Thrombosis
Obstructive Sleep Apnea and Venous Thromboembolism
There is a clear link between obstructive sleep apnea (OSA) and cardiovascular disease. However, there has been no clear link between OSA and venous thromboembolism (VTE). The objective of this study is to evaluate such a link.
- Conditions
- Obstructive Sleep Apnea, Venous Thrombosis, Pulmonary Embolism, Venous Thromboembolism
- Trial name
- OSAVTE (NCT01051297)
- Volunteers
- 85 people
- Sponsor
- University of Missouri-Columbia
Venous Thromboembolism (VTE), Pulmonary Embolism
Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)
This is an event driven Phase 3, prospective, randomized, open-label, blinded endpoint evaluation (PROBE) parallel group study in subjects with confirmed VTE.
- Conditions
- Venous Thromboembolism (VTE), Pulmonary Embolism, Deep Vein Thrombosis (DVT)
- Trial name
- NCT02798471
- Testing
- Edoxaban, Standard of Care
- Where
- 140 sites in United States, Argentina and 32 more
- Volunteers
- 290 people
- Sponsor
- Daiichi Sankyo
Venous Thromboembolism
Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants
This study is to evaluate the effects of multiple-dose clarithromycin on the single-dose pharmacokinetics (PK) of apixaban with parameters like Cmax, AUC(INF), and AUC(0-T).
- Trial name
- NCT02912234
- Testing
- Apixaban, Clarithromycin
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Cancer, Venous Thromboembolism
Prophylaxis of Venous Thrombo-Embolism in Cancer Patients Under Palliative Care
To determine the efficacy and to measure the complications of prophylactic anticoagulation using low-molecular weight heparin in adult cancer patients under palliative care
- Trial name
- NCT00303407
- Testing
- nadroparin
- Where
- Switzerland
- Sponsor
- University Hospital, Geneva
Deep Vein Thrombosis, Venous Thrombosis
Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy
Following the findings of the clinical trials in drug development, this global non-interventional cohort field study will investigate rivaroxaban under clinical practice conditions in comparison with current standard of care for…
- Trial name
- XALIA (NCT01619007)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Standard of care
- Where
- 21 sites in Austria, Belgium and 19 more
- Volunteers
- 5,145 people
- Sponsor
- Bayer
Thromboembolism
Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT)
Randomized study of PRT054021 40 mg and 15 mg bid vs. enoxaparin 30 mg q12h for the prophylaxis of venous thromboembolic events after unilateral knee replacement surgery.
- Trial name
- NCT00375609
- Testing
- Betrixaban, Enoxaparin
- Where
- Canada
- Volunteers
- 215 people
- Sponsor
- Portola Pharmaceuticals
COVID, Thrombosis
Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19
Worldwide observational studies indicate a significant prothrombogenic effect associated with SARS-CoV-2 infection with a high incidence of venous thromboembolism (VTE), notably life-threatening pulmonary embolism.
- Conditions
- COVID, Thrombosis, Pulmonary Embolism, Deep Vein Thrombosis
- Trial name
- COVI-DOSE (NCT04373707)
- Testing
- Enoxaparin
- Where
- 17 sites in France
- Volunteers
- 1,000 people
- Sponsor
- Central Hospital, Nancy, France
Thromboembolism, Arthroplasty Replacement, Knee
Safety Study of Stopping Thromboprophylaxis Based on Ultrasound Results After Total Knee Replacement
The purpose of this study is to determine whether stopping Low Molecular Weight Heparin (LMWH) thromboprophylaxis is safe after total knee joint replacement.
- Trial name
- NCT00362492
- Testing
- Bilateral ultrasound examination 7+/- 2 after surgery
- Where
- 17 sites in France
- Volunteers
- 850 people
- Sponsor
- University Hospital, Caen
Venous Thromboembolism
Thromboembolic and Hemorrhagic Complications of Anticoagulant Treatment in Patients With CAT
The study is classified as an observational pharmacological study, spontaneous, monocentric, and both retrospective and prospective for adult patients with a diagnosis of venous thromboembolism in the context of neoplasia…
- Trial name
- NCT06714734
- Where
- 2 sites in Italy
- Volunteers
- 1,000 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Critical Illness, Deep Venous Thrombosis
PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)
The purpose of this study is to evaluate the effect of Low Molecular Weight Heparin (LMWH) (Fragmin, dalteparin) versus Unfractionated Heparin (UFH) on the primary outcome of proximal leg Deep Vein Thrombosis (DVT) diagnosed by…
- Trial name
- NCT00182143
- Testing
- LMWH (Fragmin, dalteparin), Unfractionated Heparin
- Where
- 67 sites in United States, Australia and 4 more
- Volunteers
- 3,659 people
- Sponsor
- McMaster University
Anticoagulants; Circulating, Hemorrhagic Disorder
MEdication Counselling Models for Outpatient oRal antIcoaguLation
The goal of this clinical trial is to investigate whether telepharmacy-led counselling can improve medication adherence, knowledge, and hospitalisation/mortality compared with pharmacist-led counselling in adult outpatients…
- Trial name
- MEMORIAL (NCT06290440)
- Testing
- Telepharmacy-led counselling, Pharmacist-led counselling
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Gia Dinh People Hospital
Pulmonary Embolism, Venous Thromboembolism
Evaluation of the Short and Long Term Performance and Clinical Outcomes of the Crux Vena Cava Filter System
The Crux Vena Cava Filter (VCF) Registry is a clinical study, sponsored by Volcano Corporation, to evaluate the short and long term performance and clinical outcomes of the Crux Vena Cava Filter System.
- Conditions
- Pulmonary Embolism, Venous Thromboembolism, Deep Vein Thrombosis
- Trial name
- NCT02420626
- Where
- 3 sites in United States
- Sponsor
- Volcano Corporation
Pulmonary Embolism, Venous Thromboembolism
STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism
This study aims to compare the effectiveness and safety of three treatment strategies (Anticoagulation, Thrombolysis, and Mechanical Thrombectomy) for patients with intermediate-high risk acute pulmonary embolism (PE) in a…
- Trial name
- STRATEGY-PE (NCT07603700)
- Testing
- Anticoagulants, Thrombolytic Agents, Mechanical Thrombectomy Devices
- Where
- China
- Volunteers
- 1,300 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Venous Thromboembolism
Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.
The purpose of this study is to assess if 10 mg BAY59-7939, taken once daily as a tablet, is safe and prevents blood clot which may form after a knee replacement operation.
- Trial name
- RECORD 4 (NCT00362232)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin
- Where
- 124 sites in United States, Bulgaria and 11 more
- Volunteers
- 3,148 people
- Sponsor
- Bayer